GlassScriptPhysician profile
Ilyas A Chaudhry
NPI 1508854894
$4,488.05
in general payments reported to CMS, 2019-2025
28 companies · $701 in 2025
The $701 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $526 · 2020: $546 · 2021: $864 · 2022: $588 · 2023: $693 · 2024: $571 · 2025: $701.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,965.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,964.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $750.85 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $494.69 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $465.72 | 2022-2025 | Verquvo, Capvaxive |
| Abbott Laboratories | $319.55 | 2019-2024 | Gallant, Diamondback Peripheral, Diamondback Coronary |
| Abiomed | $287.22 | 2021-2025 | Impella |
| Shockwave Medical, INC | $267.03 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| E.R. Squibb & Sons, L.L.C. | $255.33 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $224.25 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $200.82 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.55 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $185.94 | 2020-2025 | Farxiga |
| Sanofi-Aventis U.S. LLC | $154.64 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $113.43 | 2019-2025 | Lifevest |
| Boston Scientific Corporation | $111.26 | 2020-2024 | Watchman Flx |
| Irhythm Technologies, INC. | $90.75 | 2020-2024 | Zio Xt Patch, Zio Monitor |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $84.25 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $41.27 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $40.67 | 2025 | Opsumit |
| Amgen INC. | $40.47 | 2023-2025 | Repatha, Repatha |
| Medtronic Vascular, INC. | $32.38 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $21.98 | 2023 | Arcalyst |
| Philips North America LLC | $20.78 | 2024 | (Cm9) Amb Mon & Diag Und |
| Glaxosmithkline, LLC. | $17.32 | 2025 | Arexvy, Shingrix |
| United Therapeutics Corporation | $17.17 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $16.31 | 2019 | |
| Baxter Healthcare | $16.26 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Medtronic, INC. | $14.40 | 2021 | |
| Novo Nordisk INC | $13.76 | 2023 | Ozempic, Rybelsus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ilyas Chaudhry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.